Haemonetics (NYSE:HAE) Earns Strong-Buy Rating from Raymond James

Raymond James reaffirmed their strong-buy rating on shares of Haemonetics (NYSE:HAE) in a report released on Friday,Benzinga reports. They currently have a $115.00 price target on the medical instruments supplier’s stock, down from their prior price target of $120.00.

Several other brokerages also recently issued reports on HAE. Bank of America downgraded shares of Haemonetics from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $95.00 to $68.00 in a research note on Friday. JMP Securities decreased their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday. Needham & Company LLC cut their price objective on Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday. Barrington Research decreased their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday. Finally, JPMorgan Chase & Co. initiated coverage on shares of Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $101.67.

Haemonetics Price Performance

Shares of Haemonetics stock opened at $59.34 on Friday. The stock has a market cap of $2.98 billion, a price-to-earnings ratio of 23.36, a price-to-earnings-growth ratio of 0.98 and a beta of 0.39. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.09 and a current ratio of 3.97. The stock has a 50 day moving average price of $76.38 and a 200-day moving average price of $78.32. Haemonetics has a one year low of $59.09 and a one year high of $97.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Equities analysts expect that Haemonetics will post 4.59 EPS for the current year.

Institutional Investors Weigh In On Haemonetics

Institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its holdings in Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 632 shares in the last quarter. Parkside Financial Bank & Trust grew its position in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 240 shares during the last quarter. AlphaQuest LLC raised its stake in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after acquiring an additional 1,826 shares in the last quarter. KBC Group NV lifted its position in Haemonetics by 54.6% during the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock valued at $157,000 after acquiring an additional 712 shares during the last quarter. Finally, iSAM Funds UK Ltd acquired a new stake in Haemonetics in the third quarter valued at approximately $204,000. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.